Literature DB >> 15671759

Antibody response to influenza vaccination in healthy adults.

Lidia B Brydak1, Skwarczyński Tadeusz, Machaka Magdalena.   

Abstract

The aim of this study was to assess antibody response in 184 healthy adults vaccinated with split influenza vaccine (Begrivac, Chiron Behring). Response to hemagglutinin and neuraminidase was assessed before vaccination and after 1 month by hemagglutination inhibition test and neuraminidase inhibition test. After vaccination, statistically significant increases of antibody titers, both for hemagglutinins and for neuraminidases, were observed. The post-vaccination proportion of persons with protective antihemagglutinin antibody titers ranged from 78.4%to 90.8%, while the proportion of persons with at least a fourfold increase of antihemagglutinin antibody titers ranged from 50.5% to 71.2%. All requirements of the Committee for Proprietary Medicinal Products regarding humoral response to inactivated influenza vaccine in healthy adults were fulfilled. Due to a wide range of age of the persons included in this study, the results were also analyzed in two age groups: from 20 to 45 years and from 46 to 56 years. Nevertheless, there were no statistically significant differences in antibody response between these two groups either for hemagglutinin or for neuraminidase.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15671759     DOI: 10.1089/vim.2004.17.609

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  6 in total

1.  Immunogenicity and safety of an inactivated 2012/2013 trivalent influenza vaccine produced in mammalian cell culture (Optaflu®): an open label, uncontrolled study.

Authors:  Christof David Vinnemeier; Johanna Fischer-Herr; Seetha Meyer; Katja Liebig; Wiebke Theeß; Gerd-Dieter Burchard; Jakob P Cramer
Journal:  Hum Vaccin Immunother       Date:  2013-11-15       Impact factor: 3.452

2.  Immunogenicity of Split Inactivated Quadrivalent Influenza Vaccine in Adults with Obesity in the 2017/2018 Season.

Authors:  Anna M Jagielska; Lidia B Brydak; Aneta S Nitsch-Osuch
Journal:  Med Sci Monit       Date:  2021-05-17

Review 3.  Quantitative review of antibody response to inactivated seasonal influenza vaccines.

Authors:  Jessica C Seidman; Stephanie A Richard; Cécile Viboud; Mark A Miller
Journal:  Influenza Other Respir Viruses       Date:  2011-06-13       Impact factor: 4.380

4.  Anti-influenza vaccination in systemic lupus erythematosus patients: an analysis of specific humoral response and vaccination safety.

Authors:  Ewa Wiesik-Szewczyk; Magdalena Romanowska; Paweł Mielnik; Hanna Chwalińska-Sadowska; Lidia B Brydak; Marzena Olesińska; Jakub Zabek
Journal:  Clin Rheumatol       Date:  2010-02-07       Impact factor: 3.650

Review 5.  Influenza diagnosis and vaccination in Poland.

Authors:  L B Brydak; A Wozniak-Kosek; A Nitsch-Osuch
Journal:  Respir Physiol Neurobiol       Date:  2013-02-16       Impact factor: 1.931

6.  Efficacy of FLU-v, a broad-spectrum influenza vaccine, in a randomized phase IIb human influenza challenge study.

Authors:  Olga Pleguezuelos; Emma James; Ana Fernandez; Victor Lopes; Luz Angela Rosas; Adriana Cervantes-Medina; Jason Cleath; Kristina Edwards; Dana Neitzey; Wenjuan Gu; Sally Hunsberger; Jeffery K Taubenberger; Gregory Stoloff; Matthew J Memoli
Journal:  NPJ Vaccines       Date:  2020-03-13       Impact factor: 7.344

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.